Showing results (411-420 of 552) with videos related to
Sort By:
Pageof 56
The Journal of Investigative Dermatology|November 4, 2018
Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult PopulationZelma C Chiesa Fuxench, Julie K Block, Mark Boguniewicz, et al.The British Journal of Dermatology|September 9, 2022
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trialsEric L Simpson, Joseph F Merola, Jonathan I Silverberg, et al.Clinical and Experimental Dermatology|November 9, 2025
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitisJonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|July 11, 2024
Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitisJonathan I Silverberg, Melinda Gooderham, Norito Katoh, et al.The Journal of Allergy and Clinical Immunology. in Practice|July 17, 2021
Association of Varying Clinical Manifestations and Positive Anti-SARS-CoV-2 IgG Antibodies: A Cross-Sectional Observational StudyJonathan I Silverberg, Israel Zyskind, Hiam Naiditch, et al.The Journal of Allergy and Clinical Immunology|December 29, 2023
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)Jonathan I Silverberg, Bruce Strober, Brian Feinstein, et al.Dermatology and Therapy|June 26, 2025
Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic DermatitisJonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 15, 2025
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 yearsChristopher G Bunick, Alan D Irvine, Jonathan I Silverberg, et al.The British Journal of Dermatology|December 4, 2023
Burden of atopic dermatitis in paediatric patients: an international cross-sectional studyStephan Weidinger, Eric L Simpson, Jonathan I Silverberg, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 28, 2026
Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 yearsMelinda J Gooderham, Jonathan I Silverberg, Marjolein De Bruin-Weller, et al.Pageof 56